Objective:To investigate and explore the serum levels of testosterone and estradiol in correlation with disease severity and prognosis in male patients with liver failure.Methods:Sixty male cases with liver failure who received treatment from April 2022 to December 2023 were selected as the research subjects. Forty healthy subjects who underwent physical examination in the physical examination center during the same period were enrolled as the control group. The levels of sex hormones (serum testosterone and estradiol) were compared between the two groups. Logistic regression was used to analyze the diagnostic value of testosterone and estradiol for the grading of male patients with liver failure. The prognostic factors for predicting disease severity were analyzed using COX regression. The area under the ROC curve (AUC) was used to evaluate the predictive value.Results:The testosterone level was significantly higher in the healthy group than that in the liver failure group [(5.11±3.00) nmol/L vs. (2.22±2.78) nmol/L, t=4.934, P<0.001], while the estradiol level was significantly lower in the liver failure group [37.46±13.21) nmol/L vs. (113.45±67.70) nmol/L, t=-8.457, P<0.001]. Multiple discriminant logistic regression analysis results showed that estradiol and testosterone were independent predictors of the model for end-stage liver disease. Multivariate Cox regression analysis showed that testosterone was an independent prognostic factor for the 1-year mortality rate in male patients with liver failure. The area under the curve predicting the 1-year mortality rate was 0.745 after adjusting for other factors. Conclusion:Testosterone and estradiol levels are significantly altered in male patients with liver failure. Testosterone and estradiol levels in peripheral blood can effectively reflect the degree of liver function impairment and the 1-year mortality rate in male patients with liver failure, which is helpful for accurately assessing the severity of the disease and its prognosis.

Objective:To investigate and explore the serum levels of testosterone and estradiol in correlation with disease severity and prognosis in male patients with liver failure.Methods:Sixty male cases with liver failure who received treatment from April 2022 to December 2023 were selected as the research subjects. Forty healthy subjects who underwent physical examination in the physical examination center during the same period were enrolled as the control group. The levels of sex hormones (serum testosterone and estradiol) were compared between the two groups. Logistic regression was used to analyze the diagnostic value of testosterone and estradiol for the grading of male patients with liver failure. The prognostic factors for predicting disease severity were analyzed using COX regression. The area under the ROC curve (AUC) was used to evaluate the predictive value.Results:The testosterone level was significantly higher in the healthy group than that in the liver failure group [(5.11±3.00) nmol/L vs. (2.22±2.78) nmol/L, t=4.934, P<0.001], while the estradiol level was significantly lower in the liver failure group [37.46±13.21) nmol/L vs. (113.45±67.70) nmol/L, t=-8.457, P<0.001]. Multiple discriminant logistic regression analysis results showed that estradiol and testosterone were independent predictors of the model for end-stage liver disease. Multivariate Cox regression analysis showed that testosterone was an independent prognostic factor for the 1-year mortality rate in male patients with liver failure. The area under the curve predicting the 1-year mortality rate was 0.745 after adjusting for other factors. Conclusion:Testosterone and estradiol levels are significantly altered in male patients with liver failure. Testosterone and estradiol levels in peripheral blood can effectively reflect the degree of liver function impairment and the 1-year mortality rate in male patients with liver failure, which is helpful for accurately assessing the severity of the disease and its prognosis.